<p>泰利福（Teleflex）已召开其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>泰利福最近的财报电话会议显示出一种平衡的情绪，突出了公司面临的优势和挑战。会议展示了令人印象深刻的收入增长和近期收购的成功整合，但也承认某些产品线和地区的困难影响了利润率，导致收入指引的修订。</p>
<h2>强劲的收入增长</h2>
<p>泰利福报告了第三季度强劲的收入数据，收入达到 9.13 亿美元，同比增加 19.4%（按 GAAP 计算）。调整后的收入也表现强劲，达到 8.929 亿美元，同比增加 16.8%（按报告计算）和 15.3%（按调整后的固定汇率计算）。</p>
<h2>血管介入业务表现</h2>
<p>泰利福最近收购的血管介入业务超出预期，同比增长 6.9%。这一表现突显了收购的战略价值及其对公司整体增长的积极贡献。</p>
<h2>血管介入业务的成功整合</h2>
<p>泰利福在整合血管介入业务方面取得了显著进展，整合活动顺利进行，进一步巩固了收购的成功。</p>
<h2>意大利回扣措施的积极影响</h2>
<p>意大利的立法变化导致准备金减少 2370 万美元，对 EMEA 地区的收入产生了积极影响。这一调整为公司在该地区的运营提供了财务支持。</p>
<h2>Barrigel 在日本的扩展</h2>
<p>泰利福通过在日本推出 Barrigel，达成了一个重要里程碑，这标志着其全球扩展战略的重要一步，并可能在亚洲市场开辟新的收入来源。</p>
<h2>主动脉内球囊泵收入下降</h2>
<p>公司在主动脉内球囊泵业务面临挑战，由于订单率低于预期，特别是在美国，导致 2025 年的收入预期减少 3000 万美元。</p>
<h2>介入性泌尿学的挑战</h2>
<p>介入性泌尿学的收入下降了 14.1%，主要是由于 UroLift 面临重大压力，尽管 Barrigel 的增长强劲。这突显了该领域内的表现不一。</p>
<h2>麻醉收入下降</h2>
<p>麻醉收入下降了 1.4%，归因于军方订单减少和气管切开管的需求疲软，表明该领域在维持增长方面面临挑战。</p>
<h2>OEM 的库存管理问题</h2>
<p>OEM 收入同比下降 3.9%，主要是由于客户的库存管理问题，反映出该领域的运营挑战。</p>
<h2>毛利率和营业利润率压力</h2>
<p>泰利福面临利润率压力，调整后的毛利率同比下降 350 个基点，主要由于关税和外汇汇率的影响。调整后的营业利润率也下降了 400 个基点，突显出运营费用的增加。</p>
<h2>前瞻性指导</h2>
<p>展望未来，泰利福提供了 2025 年的更新财务指引。公司预计调整后的固定汇率收入增长将在 6.9% 到 7.4% 之间，外汇利好为 3200 万美元。调整后的收入增长预计在 8% 到 8.5% 之间，收入范围为 33.05 亿美元到 33.20 亿美元。按 GAAP 计算，收入增长预计在 9.1% 到 9.6% 之间。调整后的毛利率预计约为 59%，关税缓解策略将影响减少到 2500 万到 2600 万美元。调整后的营业利润率预计约为 24.5%，调整后的税率约为 12.5%。调整后的每股收益预计在 14.00 美元到 14.20 美元之间。</p>
<p>总之，泰利福的财报电话会议呈现出一种平衡的前景，强劲的收入增长和成功的收购整合是主要亮点。然而，特定产品线和地区的挑战影响了利润率，迫使收入指引进行修订。公司的前瞻性指导依然乐观，预计将继续增长并进行战略财务管理。</p>

泰利福

<p>Teleflex 第三季度的财报电话会议强调了强劲的收入增长，达到了 9.13 亿美元，同比增长 19.4%，尽管某些产品线面临挑战。血管介入业务超出了预期，对整体增长产生了积极贡献。然而，主动脉内球囊泵和介入泌尿学的收入出现了下降。公司修订了 2025 年的收入指引，预计调整后的收入增长为 6.9% 至 7.4%。尽管面临利润压力，Teleflex 对未来的增长和战略财务管理仍持乐观态度</p>

<p>Teleflex ((TFX)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>泰利福（Teleflex）已召开其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Teleflex’s recent earnings call revealed a balanced sentiment, highlighting both strengths and challenges faced by the company. The call showcased impressive revenue growth and successful integration of recent acquisitions, yet acknowledged difficulties in certain product lines and regions that have impacted margins, leading to a revision in revenue guidance.</p>
<div class="lb-trans"><p>泰利福最近的财报电话会议显示出一种平衡的情绪，突出了公司面临的优势和挑战。会议展示了令人印象深刻的收入增长和近期收购的成功整合，但也承认某些产品线和地区的困难影响了利润率，导致收入指引的修订。</p>
</div><h2>Strong Revenue Growth</h2>
<div class="lb-trans"><h2>强劲的收入增长</h2>
</div><p>Teleflex reported robust revenue figures for the third quarter, with revenues reaching $913 million, marking a 19.4% increase year-over-year on a GAAP basis. Adjusted revenues were also strong at $892.9 million, reflecting a 16.8% increase year-over-year on a reported basis and a 15.3% rise on an adjusted constant currency basis.</p>
<div class="lb-trans"><p>泰利福报告了第三季度强劲的收入数据，收入达到 9.13 亿美元，同比增加 19.4%（按 GAAP 计算）。调整后的收入也表现强劲，达到 8.929 亿美元，同比增加 16.8%（按报告计算）和 15.3%（按调整后的固定汇率计算）。</p>
</div><h2>Vascular Intervention Business Performance</h2>
<div class="lb-trans"><h2>血管介入业务表现</h2>
</div><p>The Vascular Intervention business, recently acquired by Teleflex, exceeded expectations with a 6.9% year-over-year growth. This performance underscores the strategic value of the acquisition and its positive contribution to the company’s overall growth.</p>
<div class="lb-trans"><p>泰利福最近收购的血管介入业务超出预期，同比增长 6.9%。这一表现突显了收购的战略价值及其对公司整体增长的积极贡献。</p>
</div><h2>Successful Integration of Vascular Intervention</h2>
<div class="lb-trans"><h2>血管介入业务的成功整合</h2>
</div><p>Teleflex has made significant progress in integrating the Vascular Intervention business, with integration activities proceeding smoothly and on track, further solidifying the acquisition’s success.</p>
<div class="lb-trans"><p>泰利福在整合血管介入业务方面取得了显著进展，整合活动顺利进行，进一步巩固了收购的成功。</p>
</div><h2>Positive Impact of Italian Payback Measure</h2>
<div class="lb-trans"><h2>意大利回扣措施的积极影响</h2>
</div><p>Legislative changes in Italy have led to a $23.7 million decrease in reserve, positively impacting EMEA revenue. This adjustment has provided a financial boost to the company’s operations in the region.</p>
<div class="lb-trans"><p>意大利的立法变化导致准备金减少 2370 万美元，对 EMEA 地区的收入产生了积极影响。这一调整为公司在该地区的运营提供了财务支持。</p>
</div><h2>Expansion of Barrigel in Japan</h2>
<div class="lb-trans"><h2>Barrigel 在日本的扩展</h2>
</div><p>Teleflex achieved a significant milestone by launching Barrigel in Japan, marking an important step in its global expansion strategy and potentially opening new revenue streams in the Asian market.</p>
<div class="lb-trans"><p>泰利福通过在日本推出 Barrigel，达成了一个重要里程碑，这标志着其全球扩展战略的重要一步，并可能在亚洲市场开辟新的收入来源。</p>
</div><h2>Intra-aortic Balloon Pump Revenue Decline</h2>
<div class="lb-trans"><h2>主动脉内球囊泵收入下降</h2>
</div><p>The company faced challenges with its intra-aortic balloon pump segment, experiencing a decline in revenue growth due to lower-than-expected order rates, particularly in the U.S., resulting in a $30 million reduction in revenue expectations for 2025.</p>
<div class="lb-trans"><p>公司在主动脉内球囊泵业务面临挑战，由于订单率低于预期，特别是在美国，导致 2025 年的收入预期减少 3000 万美元。</p>
</div><h2>Challenges in Interventional Urology</h2>
<div class="lb-trans"><h2>介入性泌尿学的挑战</h2>
</div><p>Interventional Urology revenue saw a 14.1% decrease, mainly due to significant pressure on UroLift, despite strong growth for Barrigel. This highlights the mixed performance within the segment.</p>
<div class="lb-trans"><p>介入性泌尿学的收入下降了 14.1%，主要是由于 UroLift 面临重大压力，尽管 Barrigel 的增长强劲。这突显了该领域内的表现不一。</p>
</div><h2>Decreased Anesthesia Revenue</h2>
<div class="lb-trans"><h2>麻醉收入下降</h2>
</div><p>Anesthesia revenue decreased by 1.4%, attributed to decreased military orders and softness in tracheostomy tubes, indicating challenges in maintaining growth in this sector.</p>
<div class="lb-trans"><p>麻醉收入下降了 1.4%，归因于军方订单减少和气管切开管的需求疲软，表明该领域在维持增长方面面临挑战。</p>
</div><h2>Inventory Management Issues in OEM</h2>
<div class="lb-trans"><h2>OEM 的库存管理问题</h2>
</div><p>OEM revenue experienced a 3.9% year-over-year decline, driven by customer inventory management issues, reflecting operational challenges in this area.</p>
<div class="lb-trans"><p>OEM 收入同比下降 3.9%，主要是由于客户的库存管理问题，反映出该领域的运营挑战。</p>
</div><h2>Gross Margin and Operating Margin Pressure</h2>
<div class="lb-trans"><h2>毛利率和营业利润率压力</h2>
</div><p>Teleflex faced pressure on its margins, with an adjusted gross margin decrease of 350 basis points year-over-year due to tariffs and foreign exchange rates. The adjusted operating margin also fell by 400 basis points, highlighting increased operating expenses.</p>
<div class="lb-trans"><p>泰利福面临利润率压力，调整后的毛利率同比下降 350 个基点，主要由于关税和外汇汇率的影响。调整后的营业利润率也下降了 400 个基点，突显出运营费用的增加。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Teleflex provided updated financial guidance for 2025. The company anticipates adjusted constant currency revenue growth between 6.9% and 7.4%, with a foreign exchange tailwind of $32 million. Adjusted revenue growth is projected at 8% to 8.5%, translating to a revenue range of $3.305 billion to $3.320 billion. On a GAAP basis, revenue growth is expected between 9.1% and 9.6%. The adjusted gross margin is expected to be approximately 59%, with tariff mitigation strategies reducing the impact to $25-$26 million. The adjusted operating margin is projected to be about 24.5%, with an adjusted tax rate around 12.5%. Adjusted earnings per share are anticipated to be between $14.00 and $14.20.</p>
<div class="lb-trans"><p>展望未来，泰利福提供了 2025 年的更新财务指引。公司预计调整后的固定汇率收入增长将在 6.9% 到 7.4% 之间，外汇利好为 3200 万美元。调整后的收入增长预计在 8% 到 8.5% 之间，收入范围为 33.05 亿美元到 33.20 亿美元。按 GAAP 计算，收入增长预计在 9.1% 到 9.6% 之间。调整后的毛利率预计约为 59%，关税缓解策略将影响减少到 2500 万到 2600 万美元。调整后的营业利润率预计约为 24.5%，调整后的税率约为 12.5%。调整后的每股收益预计在 14.00 美元到 14.20 美元之间。</p>
</div><p>In summary, Teleflex’s earnings call presented a balanced outlook, with strong revenue growth and successful integration of acquisitions being key highlights. However, challenges in specific product lines and regions have impacted margins, necessitating a revision in revenue guidance. The company’s forward-looking guidance remains optimistic, with expectations of continued growth and strategic financial management.</p>
<div class="lb-trans"><p>总之，泰利福的财报电话会议呈现出一种平衡的前景，强劲的收入增长和成功的收购整合是主要亮点。然而，特定产品线和地区的挑战影响了利润率，迫使收入指引进行修订。公司的前瞻性指导依然乐观，预计将继续增长并进行战略财务管理。</p>
</div>

泰利福的财报电话会议：在挑战中实现增长